Global X Genomics & Biotechnology ETF

GNOM

Market cap $84.3M

GNOM Hedge Fund Activity: Q1 2026 in Review

40 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q1 2026, worth a combined $13.9M — down 5.9% from $14.8M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new GNOM positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 12 trimmed.

The largest buyer was Bank of America, adding an estimated $2.24M. The largest seller was Flow Traders U.S., exiting entirely with an estimated $880K sold.

• 40 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $13.9M of Global X Genomics & Biotechnology ETF stock for Q1 2026, down 5.9% quarter-over-quarter.
• 6 funds opened new Global X Genomics & Biotechnology ETF positions in Q1 2026 and 5 closed out, a net change of +1 holder.
• The largest Global X Genomics & Biotechnology ETF buyer in Q1 2026 was Bank of America, an estimated $2.24M added.
• The largest Global X Genomics & Biotechnology ETF seller in Q1 2026 was Flow Traders U.S., an estimated $880K sold.

Based on aggregated 13F filings for Q1 2026.